References in periodicals archive ?
Other possible therapies include the role of PTC124, an agent which allows 'read through' of a premature stop codon and the production of dystrophin.
A phase II trial of the oral agent PTC124 is ongoing to assess dystrophin expression and function of patients with DMD due to nonsense mutations.
PTC124 can bypass the defect in patients' protein-making machinery and improve the functioning of cell membranes, Eitan Kerem and colleagues of Hadassah Hebrew University Hospital, Jerusalem, reported in an online edition of the Lancet journal.
PTC124, which is given by mouth, is one of a number of experimental drugs in development to correct CFTR defects.
In the current trial, researchers will test PTC124 against a type of CF caused by a mutation in the salt channel gene that blocks critical protein development.
After seeing such promising results from earlier trials with PTC124, we are honored to be able to contribute to this cutting-edge study that can potentially represent a major breakthrough for our CF patients.
host disease and PTC124 for Duchenne muscular dystrophy.
A pivotal phase 2b trial of PTC124 in Duchenne muscular dystrophy (DMD) is underway, and a trial in cystic fibrosis (CF) is expected to begin during the first half of this year.
Net income in this year's third quarter reflects a $100 million licensing fee for rights to PTC124, a promising genetic disease drug in late-stage development.
PTC124 is currently being evaluated in a Phase 2b trial for Duchenne muscular dystrophy.
Medical browser ?
- psyllium husk
- psyllium hydrophilic mucilloid
- psyllium seed
- PTEN hamartoma-tumour syndromes
- PTEN-hamartoma-tumour syndromes
- pterin deaminase
- Pteris aquilina
- pteroic acid
Full browser ?
- PTC paper
- PTC paper
- PTC peptide
- PTC protein